Caribou Biosciences (NASDAQ:CRBU – Get Free Report) and SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, analyst recommendations, dividends and profitability.
Profitability
This table compares Caribou Biosciences and SOPHiA GENETICS’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Caribou Biosciences | -1,290.81% | -45.46% | -38.07% |
| SOPHiA GENETICS | -110.71% | -55.06% | -38.33% |
Analyst Recommendations
This is a summary of current ratings and recommmendations for Caribou Biosciences and SOPHiA GENETICS, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Caribou Biosciences | 0 | 0 | 5 | 0 | 3.00 |
| SOPHiA GENETICS | 0 | 1 | 4 | 0 | 2.80 |
Valuation & Earnings
This table compares Caribou Biosciences and SOPHiA GENETICS”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Caribou Biosciences | $34.48 million | 3.58 | -$102.07 million | ($1.65) | -0.83 |
| SOPHiA GENETICS | $62.37 million | 3.81 | -$78.98 million | ($1.09) | -3.33 |
SOPHiA GENETICS has higher revenue and earnings than Caribou Biosciences. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Caribou Biosciences has a beta of 2.31, suggesting that its share price is 131% more volatile than the S&P 500. Comparatively, SOPHiA GENETICS has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500.
Insider and Institutional Ownership
77.5% of Caribou Biosciences shares are owned by institutional investors. Comparatively, 31.6% of SOPHiA GENETICS shares are owned by institutional investors. 9.5% of Caribou Biosciences shares are owned by insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Caribou Biosciences beats SOPHiA GENETICS on 9 of the 14 factors compared between the two stocks.
About Caribou Biosciences
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
About SOPHiA GENETICS
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.
Receive News & Ratings for Caribou Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caribou Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
